TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Hospitalization rate in VKA patients for VTE
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Hospitalization rate in NOAC patients for VTE
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Fidelity of service provider
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of schizophrenics achieving remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of opioid use
Endpoint domain: Adverse events/effects
Primary endpoint: Progression Free Survival at 2 Years
Endpoint domain: Mortality/survival
Primary endpoint: Safety and tolerability of ABL-101
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects who seroconvert
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of end-stage renal disease (ESRD)
Endpoint domain: Mortality/survival
Primary endpoint: Oncologic Results
Endpoint domain: Mortality/survival
Primary endpoint: immediate safety
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative Seroma Formation
Endpoint domain: Adverse events/effects
Primary endpoint: Amplitude of the BOLD signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fugl-Meyer upper extremity motor function score (FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint feeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forgotten Joint Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in mean levonorgestrel concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ΔAUCPG(0-4h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTD of dual specificity CD38 and BCMA CAR-T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Copies numbers of CAR in peripheral blood, bone marrow and lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in suicidality
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Box and Blocks Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug toxicity and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in the Young Spine Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in blood glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in POMS Vigor
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in POMS Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients reporting withdrawal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of topical halofuginone
Endpoint domain: Adverse events/effects
Primary endpoint: Suicidal Risk Factors
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment success
Endpoint domain: Mortality/survival
Primary endpoint: Eradication of S. Aureus Colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Appropriate ICD therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline Quality of life (EuroQol - 5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Post-thrombectomy thrombus burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of patient with post-surgical morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: Survival rate of patients operated by the HPB Surgical Unit
Endpoint domain: Mortality/survival
Primary endpoint: Disease-free survival rate of patients operated by the HPB Surgical Unit
Endpoint domain: Mortality/survival
Primary endpoint: Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation of LDV/SOF Drug Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change of the Average Pain Intensity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal vascular network measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants reporting at least 1 treatment-emergent adverse event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with at least one histologically proven adenoma or carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Distribution of COPD patients according to GOLD 2011 grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Distribution of COPD patients according to GOLD 2011 categories of risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum Level of HE4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Monitoring of target blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Joint erosion assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Levels of Fecal Biomarkers - beta-defensins-2 (hBD-2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of Fecal Biomarkers - Fecal Calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inadequate protein intake per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inadequate protein intake per meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Meals per day with adequate protein content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total Pain Relief (TOTPAR) Over 0 to 12 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scale Of Prodromal Symptoms total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Allergen Consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lumbar ROM by inclinometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain on Numeric pain rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oesophageal pain hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Dystrophin Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological damage prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevalence of Sleep disordered breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Arterial catheterization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visual Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Closed Target Ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Anatomical MRI scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional MRI scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of subjects with serum uric acid level <6.0 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in oral health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Rate of Change in Total Area of Macular Atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to repeat therapeutic paracentesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Effectiveness by color difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: headache/pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: headache/pain frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: headache/pain duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Percentage of Participants With Vitreous Cell Count of 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virologic response (HBV DNA < 60 IU/mL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in DAS28-CRP at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiota Diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short chain fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood acetate levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Network Based Statistic (NBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early wound complications
Endpoint domain: Adverse events/effects
Primary endpoint: Motor development as measured by PDMS-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Real-world treatment patterns as assessed by FACT/NCCN-Colorectal Symptom Index-19 (FCSI-19)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Real-world treatment patterns as assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Real-world treatment patterns as assessed by EuroQoL EQ-5D-5L
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Experiencing Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate as Defined by the Investigator According to the Lugano Classification for Lymphomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Breast milk composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in soft palate elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in tongue motion assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in lips motion assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in nasal airflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Children's Depression Rating Scale-Revised
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in microbiota activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse Drug Reactions (ADR)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Assisted Hand Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prediction accuracy of survival rate
Endpoint domain: Mortality/survival
Primary endpoint: prediction accuracy of recurrent rate
Endpoint domain: Mortality/survival
Primary endpoint: Performance intelligence quotient (change from baseline)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diagnosis of Functional Constipation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastrointestinal Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pediatric Anesthesia Emergence Delirium Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of local and systemic reactogenicity events
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of volunteers with moderate or greater unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of volunteers in each group with potential immune-mediated diseases (pIMDs)
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under plasma concentration-time curve from time zero to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of sore-throat
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Successful Procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: D2 receptor density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DA release in the striatum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC based on weight/BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in proliferative markers in endometrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Reclassification of histologic grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Absolute Change From Baseline Right Ventricular Ejection Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HbA1c levels in obese patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA1c levels in patients with eGFR <90
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Influenza vaccination rates in children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful delivery of PICSO treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Difference in number of days alive without antibiotic treatment for endocarditis and/or bacteremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of early withdrawal of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Hyperdistension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of pain intensity to pinprick stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal symptom rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Presence of serotype 19A pneumococci
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum tolerated dose (MTD) of guadecitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recommended phase 2 dose (RP2D) of guadecitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety and Tolerability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aldosterone suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Incident rate of delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Incident rates of PTSD
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of myocardial perfusion imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive predictive value of myocardial perfusion imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Negative predictive value of myocardial perfusion imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rosuvastatin AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rosuvastatin Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metformin AUClast
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Metformin Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in the median pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the median ulcer size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the median ulcer number
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Grade 3 or Higher Treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Presence of phlebitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 6-month abstinence from tobacco
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnostic value of CD71 in lymphoid disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Subjects With Radiologic Evidence of Anatomic Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response Rate (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for further intervention (colposcopy)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Tsui scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Worsening Ascites (Increase in Number of Paracentesis Procedures)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Subjects With Worsening Ascites (Defined as Greater Than 2 kg Weight Gain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cases Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gastric mucosa endoscopic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gastric mucosa histopathological changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intragastric total bilirubin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gastric juice pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of UUI symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 24-hour urine leakage amount
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in patient respiratory comfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in lipid rich necrotic core (LRNC) volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Successful Tissue Expansion with Exchange to Permanent Breast Implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate of local control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Grade 2 and 3 Hand-Foot Syndrome (HFS)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in visual working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in auditory working memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Renal Function (GFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: number of patients who receive thrombolytics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: appropriateness of thrombolytic treatment decisions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consciousness level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Catheterizations Without a Leaking Accident
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction and Exit Survey Composite Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Kidney Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal Function Test (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cost of asthma health care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Decrease in systemic inflammatory response (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes